CAS 1195768-06-9

Dabrafenib mesylate

Description:

Dabrafenib mesylate is a targeted anticancer medication primarily used in the treatment of certain types of melanoma, particularly those with BRAF V600E mutations. It is a small molecule inhibitor that selectively targets and inhibits the BRAF protein, which is involved in cell signaling pathways that regulate cell growth and division. The mesylate salt form enhances its solubility and stability, facilitating its use in clinical settings. Dabrafenib mesylate is typically administered orally and is often used in combination with other therapies, such as trametinib, to improve treatment efficacy. The compound is characterized by its ability to inhibit tumor growth and is associated with various side effects, including fever, fatigue, and skin reactions. Its pharmacokinetics indicate a relatively rapid absorption and a half-life that supports once or twice daily dosing. As with many targeted therapies, monitoring for adverse effects and therapeutic response is crucial during treatment.

Formula: C₂₄H₂₄F₃N₅O₅S₃

InChI: InChI=1S/C23H20F3N5O2S2.CH4O3S/c1-23(2,3)21-30-18(19(34-21)16-10-11-28-22(27)29-16)12-6-4-9-15(17(12)26)31-35(32,33)20-13(24)7-5-8-14(20)25;1-5(2,3)4/h4-11,31H,1-3H3,(H2,27,28,29);1H3,(H,2,3,4)

InChI key: InChIKey=YKGMKSIHIVVYKY-UHFFFAOYSA-N

SMILES: FC1=C(C2=C(SC(C(C)(C)C)=N2)C3=NC(N)=NC=C3)C=CC=C1NS(=O)(=O)C4=C(F)C=CC=C4F.S(C)(=O)(=O)O

Synonyms:

• GSK 2118436 methanesulfonate salt
• GSK 2118436B
• Benzenesulfonamide, N-[3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluoro-, methanesulfonate (1:1)
• N-[3-[5-(2-Aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide methanesulfonic acid
• Dabrafenib mesylate
• Dabrafenib Mesylate (GSK2118436 Mesylate
• DABRAFENIB MESYLATE (GSK 2118436B);GSK-2118436 MESYLATE;GSK2118436 MESYLATE;GSK 2118436 MESYLATE
• N-{3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide methanesulfonic acid
• GSK2118436 Mesylate
• Dabrafenib, Methanesulfonate Salt
• N-(3-(5-(2-Aminopyrimidin-4-yl)-2-(tert-butyl)thiazol-4-yl)-2-fluorophenyl)-2,6-difluorobenzen
• Dabrfenib Mesylate
• GSK 2118436 Mesylate
• Dabrafenib Mesylate (API)
• Dapafini mesylate
• N-(3-(5-(2-Aminopyrimidin-4-yl)-2-(tert-butyl)thiazol-4-yl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide methanesulfonate
• N-[3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluoro-benzenesulfonamide methanesulfonate
• GSK-2118436 Mesylate
• GSK2118436 Ms salt, Dabrafenib Ms salt, GSK2118436A Ms salt
• abrafenibmesylate
• Dabrafenib Mesylate(GSK-2118436B)
• Dabrafenib Mesylate (GSK-2118436)
• Debrafenib Mesylate (API)

Benzenesulfonamide, N-[3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluoro-, methanesulfonate (1:1)

CAS: 1195768-06-9

Formula: C₂₄H₂₄F₃N₅O₅S₃

Purity: 99%

Color and Shape: Solid

Molecular weight: 615.6681

Ref: IN-DA000IYQ

Dabrafenib Mesylate

CAS: 1195768-06-9

Dabrafenib Mesylate

Formula: C₂₄H₂₄F₃N₅O₅S₃

Purity: ≥98%

Molecular weight: 615.67

Ref: 54-BUP13532

Dabrafenib Mesilate

CAS: 1195768-06-9

Color and Shape: Neat

Ref: 86-MM3954.00

Dabrafenib Mesylate

CAS: 1195768-06-9

Formula: C₂₃H₂₀F₃N₅O₂S₂·CH₄O₃S

Molecular weight: 519.56. 96.10

Ref: 4Z-D-108003

Dabrafenib Mesylate

CAS: 1195768-06-9

N-(3-(5-(2-Aminopyrimidin-4-yl)-2-(tert-butyl)thiazol-4-yl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide methanesulfonate

Formula: C₂₄H₂₄F₃N₅O₅S₃

Purity: 99%

Molecular weight: 615.67

Ref: IN-DG00750571

Dabrafenib Mesylate

CAS: 1195768-06-9

Dabrafenib Mesylate (GSK2118436 Mesylate) is a B-Raf inhibitor(IC50s of 0.6 and 5.0 nM for RafV600E and c-Raf, respectively).

Formula: C₂₄H₂₄F₃N₅O₅S₃

Purity: 99.45% - 99.82%

Color and Shape: Solid

Molecular weight: 615.67

Ref: TM-T8474

Dabrafenib Mesylate

CAS: 1195768-06-9

Formula: C₂₃H₂₀F₃N₅O₂S₂CH₄O₃S

Molecular weight: 519.56 : 96.10

Ref: ST-EA-CP-D127019

Dabrafenib Mesylate

Controlled Product

CAS: 1195768-06-9

Stability Hygroscopic
Applications Dabrafenib is an inhibitor of mutated BRAF kinase and has clinical activity with a manageable safety profile in clinical trials of phase 1 and 2 in patients with BRAF(V600)-mutated metastatic melanoma.
References Hauschild, A., et al.: Lancet, 380, 358 (2012); Falchook, G.S., et al.: Lancet, 379, 1893 (2012); Ascierto, P.A., et al.: J. Clin. Oncol., 31, 3205 (2013)

Formula: C₂₃H₂₀F₃N₅O₂S₂·CH₄O₃S

Color and Shape: Neat

Molecular weight: 615.67

Ref: TR-D101005

Dabrafenib mesylate

CAS: 1195768-06-9

Inhibitor of B-Raf kinase mutant

Formula: C₂₃H₂₀F₃N₅O₂S₂·CH₄O₃S

Purity: Min. 95%

Color and Shape: White/Off-White Solid

Molecular weight: 615.67

Ref: 3D-FD158016